Mr. Huitt Tracey reports
NERVGEN PHARMA GRANTS STOCK OPTIONS
Nervgen Pharma Corp. has granted 550,000 incentive stock options to directors, exercisable at a price of $2.10 per share for a period of five years, with vesting that is either time or performance based. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan.
About Nervgen Pharma Corp.
Nervgen is restoring life's potential by creating innovative solutions for the treatment of nervous system injury due to trauma or disease as a result of underlying inflammation and/or neurodegeneration. The company is initially developing drugs for the treatment of multiple sclerosis, spinal cord injury and Alzheimer's disease.
© 2021 Canjex Publishing Ltd. All rights reserved.